Información del producto
- 2,6-Pyridinediamine, N2-[(1S)-1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-2-pyrazinyl-
- N2-[(1S)-1-(4-Fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-2-pyrazinyl-2,6-pyridinediamine
- (S)-N-[1-(4-Fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N′-(pyrazin-2-yl)pyridine-2,6-diamine
- NS 018
Ilginatinib is a cell-factor inhibitor that has been identified as a potential therapeutic agent for the treatment of cancers. Ilginatinib inhibits Jak2V617F, which is an oncogenic mutation in the Jak2 gene. This mutation leads to uncontrolled growth and survival of hematopoietic cells, which are cells that produce blood cells. Ilginatinib has been shown to inhibit colony-stimulating factor (CSF), which is an inflammatory cytokine that can lead to tumor progression. The molecular modeling study indicated that ilginatinib may bind with hydrogen bonds to the active site of Jak2V617F and thereby inhibit its activity. It also prevents activation of jak2 v617f by inhibiting epidermal growth factor receptor, which is a cell surface protein. Ilginatinib also inhibits the synthesis of hematopoietic growth factors such as stem cell factor and erythropoietin, leading to decreased proliferation in these
Propiedades químicas
Consulta técnica sobre: 3D-PZB35886 Ilginatinib
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.